Dr. Laura Piqueras Ruiz

Principal Investigator
Research Group on Nuclear Receptors in Cardiometabolic Pathology


Laura Piqueras has a degree and a PhD in Pharmacy from the University of Valencia. She was awarded an Extraordinary Doctorate Award from the University of Valencia (2005).

Since 2008, she has been the Principal Investigator of competitive national projects financed by the Carlos III Health Institute and regional ones of the Generalitat Valenciana. During his postdoctoral period (2004-2006), she did a stay at the William Harvey Research Institute in London, where her research focused on the study of nuclear receptors (PPAR and RXR) and their role in vascular inflammation and angiogenesis.

Subsequently, she joined INCLIVA within the Juan de la Cierva program and later through the Miguel-Servet Type I and Type II Senior Researchers Program of the Carlos III Health Institute. Her area of research has focused on the study of the cellular and molecular mechanisms that mediate the anti-inflammatory and antiangiogenic actions of different nuclear receptors in pathologies such as abdominal aortic aneurysm, acute myocardial infarction, and obesity.

She is currently a Full Professor in the Department of Pharmacology at the University of Valencia. She teaches undergraduate courses and in the Master’s in Research and Rational Use of Medicines and in the Master’s in Biomedicine and Biotechnology at the University of Valencia. During this period she has directed numerous Doctoral Theses, Final Master’s and Final Degree Projects at INCLIVA and the University of Valencia.

She is also a member of CIBERDEM (Biomedical Network Research Center for Diabetes and Associated Metabolic Diseases), the Spanish Society of Pharmacology and the Spanish Society of Arteriosclerosis.

Dra. Laura Piqueras Ruiz
Dr. Laura Piqueras Ruiz


Anti-inflammatory effects and improved metabolic derangements in ob/ob mice by a newly synthesized prenylated benzopyran with pan-PPAR activity. Marques P, Villarroel-Vicente C, Collado A, Garcia A, Vila L, Duplan I, Hennuyer N, Garibotto F, Enriz RD, Dacquet C, Staels B, Piqueras L, Cortes D, Sanz MJ, Cabedo N. Pharmacological Research. 2023 Jan;187:106638. doi: 10.1016/j.phrs.2022.106638. PMID: 36586645

Association of chemokines IP-10/CXCL10 and I-TAC/CXCL11 with insulin resistance and enhance leukocyte endothelial arrest in obesity. Moreno B, Hueso L, Ortega R, Benito E, Martinez Hervas S, Peiro M, Civera M, Sanz MJ, Piqueras L, Real JT. Microvascular Research. 2022 Jan;139:104254. doi: 10.1016/j.mvr.2021.104254. PMID: 34534571

Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players. Marques P, Domingo E, Rubio A, Martinez-Hervas S, Ascaso JF, Piqueras L, Real JT, Sanz MJ. Biomedicine & Pharmacotherapy. 2022 Jan;145:112460. doi: 10.1016/j.biopha.2021.112460. PMID: 34864314

Activation of the constitutive androstane receptor inhibits leukocyte adhesiveness to dysfunctional endothelium. Lopez-Riera M, Ortega R, Hueso L, Montesinos MC, Gomez-Cabrera MC, Sanz MJ, Real JT, Piqueras L. International Journal of Molecular Sciences. 2021 Aug 27;22(17):9267. doi: 10.3390/ijms22179267. PMID: 34502180

An updated overview of e-cigarette impact on human health. Marques P, Piqueras L, Sanz MJ. Respiratory Research. 2021 May 18;22(1):151. doi: 10.1186/s12931-021-01737-5. PMID: 34006276

Dissecting abdominal aortic aneurysm is aggravated by genetic inactivation of LIGHT (TNFSF14). Herrero-Cervera A, Espinos-Estevez C, Martin-Vano S, Taberner-Cortes A, Aguilar-Ballester M, Vinue A, Piqueras L, Martinez-Hervas S, Gonzalez-Navarro H. Biomedicines. 2021 Oct 22;9(11):1518. doi: 10.3390/biomedicines9111518. PMID: 34829747

Oral unsaturated fat load impairs postprandial systemic inflammation in primary hypercholesterolemia patients. Collado A, Domingo E, Marques P, Perello E, Martínez-Hervás S, Piqueras L, Ascaso JF, Real JT, Sanz MJ. Frontiers in Pharmacology. 2021 Apr 20;12:656244. doi: 10.3389/fphar.2021.656244. PMID: 33959024

Peripheral blood levels of CXCL10 are a useful marker for diabetic polyneuropathy in subjects with type 2 diabetes. Ascaso P, Palanca A, Martinez-Hervas S, Sanz MJ, Ascaso JF, Piqueras L, Real JT. International Journal of Clinical Practice. 2021 Aug;75(8):e14302. doi: 10.1111/ijcp.14302. PMID: 33930221

Postprandial triglyceridemia is modulated by insulin resistance but not by grade of obesity in abdominal and morbid obese subjects. Moreno-Perez B, Benito E, Civera M, Alabadi B, Martinez-Hervas S, Peiro M, Gonzalez-Navarro H, Piqueras L, Jesus Sanz M, Ascaso J, Real J. International Journal of Clinical Practice. 2021 Apr;75(4):e13776. doi: 10.1111/ijcp.13776. PMID: 33089594

Role of antiangiogenic VEGF-A165b in angiogenesis and systolic function after reperfused myocardial infarction. Rios Navarro C, Hueso Soler L, Diaz Cuevas A, Marcos Garcés V, Bonanad Lozano C, Ruiz Sauri A, Vila Salinas J, Sanz Ferrando M, Chorro Gascó F, Piqueras Ruiz L, Bodí Peris V. Revista espanola de Cardiologia (English ed.). 2021 Feb;74(2):131-139. doi: 10.1016/j.rec.2020.03.013. PMID: 32474003

The nuclear retinoid-related orphan receptor RORalpha controls adipose tissue inflammation in patients with morbid obesity and diabetes. Ortega R, Hueso L, Benito E, Ortega J, Civera M, Sanz M, Real J, Piqueras L. International Journal of Obesity. 2021 Jul;45(7):1369-1381. doi: 10.1038/s41366-021-00787-5. PMID: 33637954

Angiotensin II and leukocyte trafficking: New insights for an old vascular mediator. Role of redox-signaling pathways. Piqueras Ruiz L, Sanz Ferrando M. Free Radical Biology and Medicine. 2020 Sep;157:38-54. doi: 10.1016/j.freeradbiomed.2020.02.002. PMID: 32057992

Reference: PI21/00220
Title: Estudio de nuevos ejes de quimiocinas como potenciales dianas de intervención en la obesidad y la resistencia a la insulina
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Laura Piqueras Ruiz, José Tomas Real Collado
Duration: 2022 – 2024
Total budget: 204.490 €
Reference: CDEI0420A
Title: Plan GenT
Funding body: Conselleria de Sanidad
Principal Investigator: Laura Piqueras Ruiz
Duration: 2020 – 2023
Total budget: 253500
Reference: PI18/00209
Title: Identificación de nuevos mecanismos implicados en la angiogénesis e inflamación en pacientes obesos. Modulación por ligandos de receptores nucleares constitutivos de androstano
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Laura Piqueras Ruiz, José Tomas Real Collado
Duration: 2019 – 2022
Total budget: 173.333 €
Reference: PIE15/00013
Title: A multidisciplinary Project to advance in basic mechanisms, diagnosis, prediction, and prevention of cardiac damage in reperfused acute myocardial infarction
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Vicente Bodí Peris
Duration: 2016 – 2019
Total budget: 589.050 €
+ Info
Title: Effect of SGLT-2 inhibition in abdominal aortic aneurysm development. Role of rora in adipose tissue inflammation associated to obesity
Doctoral candidate: Ortega Herráiz, Rebeca
Director(s): Piqueras Ruiz, Laura; Sanz Ferrando, María Jesús; Real Collado, José Tomás
Date of the defense: 21/02/2022
University: Universitat de València

Title: Chemokine axes and inflammatory status in metabolic syndrome. Effect of pcsk9 inhibitors in the systemic inflammation associated to familial hypercholesterolemia
Doctoral candidate: Gomes Marques, Patrice
Director(s): Piqueras Ruiz, Laura; Sanz Ferrando, María Jesús
Date of the defense: 07/02/2020
University: Universitat de València

Title: Study of the systemic inflammation associated to primary hypercholesterolemia, its modulation and its impact in atherosclerosis. Role of cxcl16/cxcr6 axis in abdominal aortic aneurysm formation
Doctoral candidate: Collado Sánchez, Aida
Director(s): Sanz Ferrando, María Jesús; Piqueras Ruiz, Laura
Date of the defense: 22/07/2019
University: Universitat de València